BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 16979993)

  • 1. Comparison of enteric-coated mycophenolate sodium with mycophenolate mofetil in living renal allograft transplantation.
    Minz M; Sharma A; Heer M
    Transplant Proc; 2006 Sep; 38(7):2041-3. PubMed ID: 16979993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients.
    Budde K; Glander P; Diekmann F; Dragun D; Waiser J; Fritsche L; Neumayer HH
    Transplant Proc; 2004 Mar; 36(2 Suppl):524S-527S. PubMed ID: 15041401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mycophenolate mofetil versus enteric-coated mycophenolate sodium: a large, single-center comparison of dose adjustments and outcomes in kidney transplant recipients.
    Sollinger HW; Sundberg AK; Leverson G; Voss BJ; Pirsch JD
    Transplantation; 2010 Feb; 89(4):446-51. PubMed ID: 20177347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enteric-coated mycophenolate sodium given in combination with tacrolimus has a lower incidence of serious infections in Asian renal-transplant recipients compared with mycophenolate mofetil.
    Feng JJ; Zhang LW; Zhao P; Bow LM; Tian J
    Int J Clin Pract Suppl; 2015 May; (183):1-7. PubMed ID: 26176848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of tolerability and ability to increase immunosuppression in renal transplant patients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium.
    Bilodeau JF; Montambault P; Wolff JL; Lemire J; Masse M
    Transplant Proc; 2009 Nov; 41(9):3683-9. PubMed ID: 19917367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enteric-coated mycophenolate sodium: therapeutic equivalence to mycophenolate mofetil in de novo renal transplant patients.
    Sollinger H
    Transplant Proc; 2004 Mar; 36(2 Suppl):517S-520S. PubMed ID: 15041399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients.
    Massari P; Duro-Garcia V; Girón F; Hernández E; Juárez F; Castro C; Toledo M;
    Transplant Proc; 2005 Mar; 37(2):916-9. PubMed ID: 15848574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium.
    Ortega F; Sánchez-Fructuoso A; Cruzado JM; Gómez-Alamillo JC; Alarcón A; Pallardó L; Morales JM; Oliver J; Guinea G;
    Transplantation; 2011 Aug; 92(4):426-32. PubMed ID: 21760569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing outcomes associated with dose manipulations of enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients.
    Cooper M; Deering KL; Slakey DP; Harshaw Q; Arcona S; McCann EL; Rasetto FA; Florman SS
    Transplantation; 2009 Aug; 88(4):514-20. PubMed ID: 19696634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superior efficacy of enteric-coated mycophenolate vs mycophenolate mofetil in de novo transplant recipients: pooled analysis.
    Salvadori M; Bertoni E; Budde K; Holzer H; Civati G; Lien B; Arns W
    Transplant Proc; 2010 May; 42(4):1325-8. PubMed ID: 20534293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stable renal transplant recipients can be safely converted from MMF to enteric-coated mycophenolate sodium tablets: Interim results of a multicenter Latin American study.
    Abbud-Filho M; Girón F; Hernández E; Juarez F; Liendo C; Novoa P; Toledo M;
    Transplant Proc; 2004; 36(6):1647-9. PubMed ID: 15350440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study.
    Budde K; Curtis J; Knoll G; Chan L; Neumayer HH; Seifu Y; Hall M;
    Am J Transplant; 2004 Feb; 4(2):237-43. PubMed ID: 14974945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life in renal transplant recipients following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium.
    Cofan F; Rosich E; Arias M; Torregrosa V; Oppenheimer F; Campistol JM
    Transplant Proc; 2007 Sep; 39(7):2179-81. PubMed ID: 17889130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enteric-coated mycophenolate sodium reduces gastrointestinal symptoms in renal transplant patients.
    Burg M; Säemann MD; Wieser C; Kramer S; Fischer W; Lhotta K
    Transplant Proc; 2009 Dec; 41(10):4159-64. PubMed ID: 20005359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study.
    Kobashigawa JA; Renlund DG; Gerosa G; Almenar L; Eisen HJ; Keogh AM; Lehmkuhl HB; Livi U; Ross H; Segovia J; Yonan N;
    J Heart Lung Transplant; 2006 Aug; 25(8):935-41. PubMed ID: 16890114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic).
    Budde K; Knoll G; Curtis J; Chan L; Pohanka E; Gentil M; Seifu Y; Marrast AC; Neumayer HH;
    Clin Nephrol; 2006 Aug; 66(2):103-11. PubMed ID: 16939066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolate mofetil versus enteric-coated mycophenolate sodium after simultaneous pancreas-kidney transplantation.
    Rangel EB; Melaragno CS; Sá JR; Gonzalez AM; Linhares MM; Salzedas A; Medina-Pestana JO
    Transplant Proc; 2009 Dec; 41(10):4265-9. PubMed ID: 20005381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of inosine-monophosphate-dehydrogenase activity in patients with enteric-coated mycophenolate sodium or mycophenolate mofetil after renal transplantation.
    Rath T; Küpper M
    Transplant Proc; 2009; 41(6):2524-8. PubMed ID: 19715967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enteric-coated mycophenolate-sodium in heart transplantation: efficacy, safety, and pharmacokinetic compared with mycophenolate mofetil.
    Lehmkuhl H; Hummel M; Kobashigawa J; Ladenburger S; Rothenburger M; Sack F; Dengler T; Hetzer R
    Transplant Proc; 2008 May; 40(4):953-5. PubMed ID: 18555088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplantation with tacrolimus and steroid avoidance: four-year analysis.
    Ciancio G; Gaynor JJ; Zarak A; Sageshima J; Guerra G; Roth D; Brown R; Kupin W; Chen L; Tueros L; Hanson L; Ruiz P; Burke GW
    Transplantation; 2011 Jun; 91(11):1198-205. PubMed ID: 21107305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.